A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction

Documenti analoghi

• Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
  di: Sibylle Cocciardi, et al.
  Pubblicazione: (2025)
• APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
  di: Francesco Mannelli, et al.
  Pubblicazione: (2026)
• Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
  di: Frank G. Rücker, et al.
  Pubblicazione: (2024)
• Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
  di: Jan‐Niklas Eckardt, et al.
  Pubblicazione: (2025)
• Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML
  di: Uta Oelschlaegel, et al.
  Pubblicazione: (2025)